Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Open Source Drug Discovery Initiative Compiles The TB Genome; Calls For Stronger Global Partnerships For Leads

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A decade after the mycobacterium tuberculosis genome sequence was deciphered, the Indian government's ambitious Open Source Drug Discovery initiative released what is claimed to be the first-ever comprehensive compilation of the mapped TB genome. The collated data will be made available through an open public portal for further analysis, leads and research collaborations
Advertisement

Related Content

Janssen Plans Tiered Pricing For Sirturo In India; Will Work With Government Agencies For Right Use
Janssen Plans Tiered Pricing For Sirturo In India; Will Work With Government Agencies For Right Use
Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers
Big Pharmas Come Together On TB, But Effort To Accelerate Development May Hit Speedbump From Lack Of Biomarkers
Advertisement
UsernamePublicRestriction

Register

SC074522

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel